The Week In Review In Prescription Drug Pricing

The week in drug pricing has been marked with dormant dashboards, broken promises and bloated CEO salaries.

So, let’s get to it.

1. Dormant drug dashboards

  • HHS has not updated the databases that tell the public how much money the government is paying for drugs. The inaction follows repeated promises from President Trump that "one of my greatest priorities is to reduce the price of prescription drugs.” — (CNN)

2. “We were forced to file for bankruptcy to afford my insulin.”

3. Piles of gold skimmed off the backs of the sick and dying.

  • Eye-popping CEO salaries that are, umm, not investments in R&D? — (Axios

4. Kickback schemes at Novartis?

  • The accusations flying are sick, and yet, not surprising. — (STAT)

5. The Vertex CEO said a few things he might regret.

Have a wonderful weekend, everyone. See you next week!